selfrighteousbull
Posted - 2 weeks ago
$SMCI nvda to replace smci lmao $sgtx here we go
Chiasma
Posted - 1 month ago
$PPBT SEC is in bed with shorts, take $MMTLP for a starting lesson. Look shorts aren’t budging for whatever idiotic reason, other than they get away with it. So large and small pharmas have to be clever like they were with $SGTX and come up with a CVR deal and fuck over the shorts bigly. https://www.fiercebiotech.com/biotech/lilly-raiding-biotech-bargain-bin-buys-diabetes-cell-therapy-partner-sigilon-35m
NVDAMillionaire
Posted - 3 months ago
$SGTX Sigilon Therapeutics, Inc. (NASDAQ:SGTX): Pioneering a New Class of Engineered Cell Therapies http://beyondspx.com/2024/08/05/sigilon-therapeutics-inc-nasdaqsgtx-pioneering-a-new-class-of-engineered-cell-therapies/
GenevieveRamirez
Posted - 5 months ago
$SGTX 🙏👇👇
badgermobile
Posted - 5 months ago
@mean_indean $AKBA$mcrb $SGTX We see the same happening at AKBA as drug is now approved but waiting to ship product and the hedgies are scaring people away
Chiasma
Posted - 6 months ago
@baurzhan16 Yes you need to read the deal $SGTX started at $3/shares and deal was for $130/share
Under the terms of the definitive agreement, Lilly will commence a tender offer to acquire all outstanding shares of Sigilon for a purchase price of $14.92 per share in cash (an aggregate of approximately $34.6 million) payable at closing, plus one non-tradeable contingent value right ("CVR") per share that entitles the holder to receive up to an additional $111.64 per share in cash, for a total potential consideration of up to $126.56 per share in cash without interest (an aggregate of up to approximately $309.6 million excluding shares held by Lilly).
demetrin
Posted - 6 months ago
@buythehornz127 @StillnessofBreath @Jeko44 @Investman13 @Fiftybucks Premium over some biotechnology bought out $PRVB $6.70 to $25 which was a 273% premium over the previous closing price
Bought by SANOFI
$CCXI to $24.11 to $52 which was a 116% premium over the previous closing price.
Bought by AMGEN
$GWPH $146.25 to $200 cash & $20 in Jazz stock Per share which was 50% premium over closing price.
Bought by JAZZ
$SGTX $3.93 to $22.47 which was 472% premium
Bought by LILLY
$CBAY $25.69 to $32.50 represents 27% premium over closing price Bought by GILEAD
mean_indean
Posted - 7 months ago
$MCRB $SGTX (Sigilon) got down to a split adjusted (12:1) price of .31 before the buyout. Patience.
Chiasma
Posted - 03/28/24
$HEPA I envision a deal very similar to $SGTX I see them perhaps releasing some data early to give a glimpse, this runs to $20/share, we get a deal for $30/share and then it becomes structured. $50/share with completion of phase IIb, $50/share with completion of phase III, and $50/share with PDUFA acceptance. https://www.fiercebiotech.com/biotech/lilly-raiding-biotech-bargain-bin-buys-diabetes-cell-therapy-partner-sigilon-35m
Who_is_JohnnyGalt
Posted - 8 months ago
$MCRB $SGTX True but SGTX also did a 1 for 13 rss on May 23, 2023.
SwordfishTrader
Posted - 8 months ago
$MCRB $SGTX useful analogy and reminder. See the forest through the trees and have patience if you are sure of the VALUE here. Numbers don’t lie and math adds up.
mean_indean
Posted - 8 months ago
$MCRB Sigilon therapeutics $SGTX 2/28/23 - exec team given shares ($15 sp)
6/28/23 - price hits $3.82
6/29/23 - price hits $28 after Eli Lilly Acquisition Seres therapeutics
2/16/24 - exec team given shares ($1.06 sp)
…..
…..
trf07
Posted - 8 months ago
$CELZ Know what you hold. $PRVB was into T1 Diabetes therapy also and was bought at 2.9 billion $. $SGTX also early stage T1 Diabetes therapy was bought for more than 300 milliy$. CELZ mcap currently 9 mill. 😎
EddieH2020
Posted - 10 months ago
$EFTR Fun fact:
$SGTX did a 1 for 13 reverse split on 5/23/23, only to get bought out by $LLY with buyout news hitting less than 6 weeks after.
You really just never know 🤷🏼♂️
GSMITH10107
Posted - 10 months ago
@Kremm not for biotechs - see $VTGN $CRIS $ORTX $SGTX ALL up multiples since reverse split just depends on managements intentions IMO
GSMITH10107
Posted - 10 months ago
$EFTR alot of biotechs reverse split names that have done extremely well post RS I think its not viewed as it used to be especially with amazing management. ($EFTR management team is great) think $HARP $SGTX $CRIS all doing amazing post reverse split however my personal investment thesis relies on 2024 and the data that is released selling pressure might subside especially when there isn't 75 million shares floating around
GSMITH10107
Posted - 10 months ago
$EFTR knew they would RS but not worried as $SGTX got bought out for a huge premium after RS AND $HARP
barkemylou
Posted - 12/30/23
@RMcCourt600 It is all about making money my friend. That was a small profit. $CING $SGTX $CGA much better
BiotechValues
Posted - 12/22/23
@Odintrading @RallyRaider correct. And a R/S means nothing. $SGTX did a 1:13 R/S, dropped shares to 2.5M O/S, and was bought out by its partner Lilly a month after.
Chief_EZ
Posted - 1 year ago
$FNCH imagine waking up one day to a buyout of $15 a share like $SGTX
RallyRaider
Posted - 1 year ago
$SRZN If you believe in positive data or any partnerships or M&A action, there will be bidders leaving the table and thus suppressing price before the actual event happens. look at the charts of the recent fancy names out there $TPST $SLNO $SGTX
Day3
Posted - 1 year ago
$UBX I think they are about to be bought out. Why would they pay off a $16m loan early when they didn't need to? $SGTX did same and Lilly bought them out 38 days after they paid off their loan. UBX once valued at $300m, now sitting at $30m valuation with $70m cash and reasonable burn rate. DME market is in the billions and this is the cheapest drug to buy with comparable efficacy to Eylea. UBX won't have/be able to raise the funds to take this all the way and a bigger player would rather buy it on the cheap rather than partner up. Also, bigger player can focus future trials on a more unmet need area rather than compete with Eylea et al. A lot of money has already been spent derisking UBX-1325 so makes it an ideal product to buy on the cheap.
A $5-6 per share upfront offer with tasty, achievable tiered CVRs should do the trick. All speculation on my part, but makes total sense to me. If a buy-out happens, I'm betting on October.
BioCEOsSukk
Posted - 09/29/23
So $LLY bought $SGTX for 381 percent of the share price plus CVRs for about 10x that.
For $OPGN, the cash part at today's closing price would be around 1.53 - and they could do a $7.50 CVR for UTI approval each in USA and China.
If you're watching Yvonne - this is your blueprint to finish the deal this weekend...
SmallCapManager
Posted - 09/28/23
@Joefallin @Alexii Pretty sure I was correct on $CABA, $SGTX, $STSA and others but keep nitpicking ones that haven’t materialized yet my number 1 fan! It also gives me pleasure to stay in your head rent free. Cheers 🍻
IDKstocksanymore
Posted - 09/26/23
$SGTX what happened to this stock, cannot find the ticker to trade
Gohan89
Posted - 1 year ago
$SGTX up almost 200 percent in a year. Did this rs? Or just good news?
randy212
Posted - 1 year ago
@BullFisher00 I can see you are a long time Investor so you know better but you may want to look at $SGTX after r/s. Something definetly cooking here with huge volume.
zedma
Posted - 08/27/23
@MBA_Certified and same with $SGTX, some losers like you were crying that Lilly is overpaying,🤣😂🤣😂
biostock
Posted - 08/23/23
$CELZ When stock is range bound and getting impatient just read the $LLY deal for $SGTX . Whole bio sector is in the shorts clutches for now but when it takes off i expect it to make it up big time. My guesstimate is BPs are awaiting green light for flurry of deals across the sector.